- Home
- XXII vs CPHI Comparison
XXII vs CPHI Comparison
Compare XXII & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- CPHI
- Stock Information
- Founded
- XXII 1998
- CPHI N/A
- Country
- XXII United States
- CPHI China
- Employees
- XXII N/A
- CPHI N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- CPHI Health Care
- Exchange
- XXII Nasdaq
- CPHI Nasdaq
- Market Cap
- XXII 4.0M
- CPHI 4.2M
- IPO Year
- XXII N/A
- CPHI N/A
- Fundamental
- Price
- XXII $0.09
- CPHI $0.19
- Analyst Decision
- XXII
- CPHI
- Analyst Count
- XXII 0
- CPHI 0
- Target Price
- XXII N/A
- CPHI N/A
- AVG Volume (30 Days)
- XXII 9.6M
- CPHI 385.4K
- Earning Date
- XXII 11-12-2024
- CPHI 11-13-2024
- Dividend Yield
- XXII N/A
- CPHI N/A
- EPS Growth
- XXII N/A
- CPHI N/A
- EPS
- XXII N/A
- CPHI N/A
- Revenue
- XXII $9,918,000.00
- CPHI $5,544,620.00
- Revenue This Year
- XXII $56.94
- CPHI N/A
- Revenue Next Year
- XXII $2.98
- CPHI N/A
- P/E Ratio
- XXII $0.03
- CPHI N/A
- Revenue Growth
- XXII N/A
- CPHI N/A
- 52 Week Low
- XXII $0.09
- CPHI $0.17
- 52 Week High
- XXII $5.28
- CPHI $1.15
- Technical
- Relative Strength Index (RSI)
- XXII 31.38
- CPHI 32.94
- Support Level
- XXII $0.09
- CPHI $0.18
- Resistance Level
- XXII $0.13
- CPHI $0.27
- Average True Range (ATR)
- XXII 0.01
- CPHI 0.02
- MACD
- XXII 0.01
- CPHI -0.01
- Stochastic Oscillator
- XXII 10.51
- CPHI 13.22
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.